HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SCLX
Scilex Holding Company
There isn't enough reported data to score SCLX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SCLX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
SCLX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SCLX PE Valuation
SCLX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.5x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SCLX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect SCLX to return to profit, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SCLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | — |
| Q3 2025 | -$31.88 | -$3.18 |
SCLX has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SCLX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SCLX on profitability, with a higher operating margin.
SCLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.6M | -23% |
| Q1 2026 | $8.6M | +72% |
| Q4 2025 | $4.8M | -68% |
| Q3 2025 | $10.6M | -27% |
| Q2 2025 | $9.9M | -40% |
| Q1 2025 | $5M | -54% |
| Q4 2024 | $14.9M | +11% |
| Q3 2024 | $14.4M | +43% |
SCLX's revenue has slid since its 2024 peak: $8M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -385% | -178 points |
| Q1 2026 | -373% | +184 points |
| Q4 2025 | -2318% | -2127 points |
| Q3 2025 | -1766% | -1628 points |
| Q2 2025 | -207% | -112 points |
| Q1 2025 | -558% | -379 points |
| Q4 2024 | -190% | -54 points |
| Q3 2024 | -138% | +246 points |
SCLX's operating margin was −385% last quarter, down 178 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
SCLX has the stronger cash trend. Its trailing FCF is up 271% versus its history, compared with HIMS at down 84%.
SCLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | -118% |
| Q3 2025 | $8.2M | +61% |
| Q1 2025 | $6M | -36% |
| Q4 2024 | $2.5M | +$7.9M |
| Q3 2024 | $5.1M | -13% |
| Q1 2024 | $9.4M | +$17.1M |
| Q3 2023 | $5.9M | +$6.2M |
| Q1 2023 | -$7.7M | -$6.9M |
SCLX usually generates cash, though not every quarter: the latest was −$1M, but it generated $20M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SCLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -115K shares |
| 1 year | -24% | -116K shares |
SCLX has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SCLX Net Leverage
SCLX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SCLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 0.8 | Oversold |
SCLX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SCLX PE vs Healthcare Sector
| Metric | SCLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCLX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SCLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.77 | 44% below |
| 20 week MA | $5.09 | 69% below |
| 50 week MA | $7.45 | 79% below |
| 100 week MA | $10.2 | 85% below |
| 200 week MA | $62.2 | 97% below |
SCLX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SCLX on returns for 2026, with the stronger performance.
SCLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $344.8 | $351.4 | +1.9% |
| 2022 | $351.4 | $117.3 | -67% |
| 2023 | $117.3 | $71.4 | -39% |
| 2024 | $71.4 | $13.7 | -81% |
| 2025 | $13.7 | $14.1 | +3.3% |
| 2026 YTD | $14.1 | $1.56 | -89% |
SCLX has finished lower in three of the last five years. It's down 89% so far in 2026.